


Pay just \$5\* per dose of ILUMYA®



- The ILUMYA® Copay Program is available for eligible patients with commercial healthcare insurance
- With the ILUMYA® Copay Program, you don't need to carry an actual card. Instead, your digital copay card can be accessed at ILUMYA.com at any time

\*Eligible commercially insured patients 18 years or older may pay as little as \$5 per dose for an ILUMYA® prescription, subject to a \$16,000 maximum annual program benefit. After the program maximum, patients will be responsible for the difference. This offer is valid only for patients who meet the program eligibility requirements, have commercial insurance that covers ILUMYA®, and have a valid prescription. One digital card per patient, not transferable, and cannot be combined with any other offer.



Visit **ILUMYA.com/activate** to find out more about these programs.



The ILUMYA registered trademarks are the property of Sun Pharma Global FZE.  
© 2021 Sun Pharmaceutical Industries, Inc. All rights reserved.  
PM-US-ILY-1551 08/2021



## FINANCIAL SUPPORT



THE FINANCIAL OPTIONS AVAILABLE TO YOU FROM  
ILUMYA SUPPORT LIGHTING THE WAY®

### GET HELP WITH:

- ILUMYA® Early Access Program
- ILUMYA® Copay Program
- ILUMYA® Patient Assistance Program



# ILUMYA SUPPORT

LIGHTING THE WAY®

## 3 ways to activate your account



Text **ACTIVATE** to 20808



Visit **ILUMYA.com/activate**



Call **855-4ILUMYA (855-445-8692)**



## Learn about ILUMYA® low- or no-cost options based on your type of insurance

### ILUMYA® EARLY ACCESS PROGRAM

If you have commercial insurance, you will be automatically enrolled in this program and are eligible to receive ILUMYA® (tildrakizumab-asmn) for free for up to 2 years.\*

### ILUMYA® COPAY PROGRAM

With the ILUMYA® Copay Card, eligible patients with commercial insurance may pay no more than \$5<sup>†</sup> per dose.

### ILUMYA® PATIENT ASSISTANCE PROGRAM

If you do not have enough insurance coverage or do not have insurance at all, you may be eligible to receive ILUMYA® at no cost through the Patient Assistance Program. Income documentation is required. Subject to terms and conditions.

### MEDICARE PART B

Because ILUMYA® is a biologic medicine that is injected in the office by a medical professional, it is covered by Medicare Part B as a medical benefit. Most people with Medicare Part B coverage could pay \$0 for ILUMYA®.<sup>‡</sup>

<sup>\*</sup>Eligibility rules apply. Patients must be commercially insured. For patients to remain eligible for the Early Access Program, providers must submit a medical and/or pharmacy prior authorization form before a patient's third dose. See full terms and conditions at [ILUMYA.com/savings](https://www.ilumya.com/savings).

<sup>†</sup>Eligible commercially insured patients 18 years or older may pay as little as \$5 per dose for an ILUMYA® prescription, subject to a \$16,000 maximum annual program benefit. After the program maximum, patients will be responsible for the difference. This offer is valid only for patients who meet the program eligibility requirements, have commercial insurance that covers ILUMYA®, and have a valid prescription. One digital card per patient, not transferable, and cannot be combined with any other offer.

<sup>‡</sup>Medicare Part B coverage has a 20% cost share for ILUMYA®, but with supplemental insurance, your prescription may be covered in full.

## Activate your account today

With enrollment in ILUMYA SUPPORT Lighting the Way®, you'll receive personalized email and text message support, and, if you're eligible, financial support that can make the cost of ILUMYA® (tildrakizumab-asmn) more affordable.

### The ILUMYA SUPPORT Lighting the Way® program can help you:

- Find assistance with paying for ILUMYA®
- Get started with ILUMYA®
- Stay on track with your treatment

By activating, you agree to receive marketing and other loyalty program text messages and emails, including messages sent using an autodialer. You understand that consent is not required as a condition of purchase.



 **ILUMYA®**  
tildrakizumab-asmn  
Injection 100 mg/mL